...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Internet Journal of Alternative Medicine >Normalization Of Liver Enzyme Levels In A Patient With Chronic Hepatitis C Virus Infection Treated By Ribavirin Placed Into The Field Of Unusual Properties Of Low Level Laser Radiation: Case Report And Review Of Literature.
【24h】

Normalization Of Liver Enzyme Levels In A Patient With Chronic Hepatitis C Virus Infection Treated By Ribavirin Placed Into The Field Of Unusual Properties Of Low Level Laser Radiation: Case Report And Review Of Literature.

机译：利巴韦林治疗的慢性丙型肝炎病毒感染患者肝酶水平的正常化，该研究被置于低强度激光辐射异常性质领域：病例报告和文献复习。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chronic hepatitis C is a major cause of chronic liver disease globally, and the natural history of progression may lead to cirrhosis with liver failure, hepatocellular carcinoma, and premature liver-related death. We present the case of a 24-year-old Asian man with chronic hepatitis C virus infection 1 genotype treated by ribavirin placed into the field formed by low level laser radiation and transmitted through the light-guide. The administrated therapy resulted in stabilization of the pathological processes accompanied by the normalization of serum alanine-aminotransaminase and gamma-glutamyltransferase levels, improvement of patient’s condition and his quality of life. No side effects in applying the aforementioned method were observed. Introduction The current treatment of chronic hepatitis C (HCV) is peginterferon alfa-2a or alfa-2b plus ribavirin, which had a sustained virological response after 48 weeks of combination therapy in pivotal trials in approximately 42% to 52% of patients with a genotype 1 infection1-3. The primary goal of treatment of chronic HCV is to prevent late liver-related morbidity and mortality; however treatment of HCV has traditionally been difficult because of high rates of treatment discontinuation due to the side effects of pegintereferon therapy4. Ribavirin is an oral nucleoside analog, which is well tolerated and appears to decrease HCV infectivity in a dose-dependent manner, but its mode of action is not completely understood5. Monotherapy with ribavirin is associated with an end-of-treatment biochemical response and improvement in histology, which result in normalization or near normalization of serum aminotransferase levels, but it is ineffective in eliminating HCV RNA6,7. In this paper, we present a case of chronic HCV infection treated by ribavirin, placed into the field formed by low-level laser radiation transmitted through the light-guide, that has resulted in long-lasting normalization of serum aminotransferase levels. To the best of our knowledge, this is the first case report of treatment of a patient with chronic HCV infection by this method. Case report In September 2005, a 24-year-old, single Asian man, BMI-17.9, presented to the Outpatient Department of the Institute of Virology with complaints of lethargy, fatigue, periodical pain in the epigastrium, nausea and heartburn. His medical history included a single blood transfusion episode in his early childhood and the surgical intervention caused by a foot wound in 2001. In January 2005, the patient started complaining of the aforementioned symptoms, and the examination found a high level of alanine aminotransferase (ALT). The patient tested positive for HCV RNA (qualitative). In March 2005, the therapy with pegylated interferon alfa (PEG-INF) and ribavirin was started. The drugs were administered according to the standard protocol. However, due to complaints of weakness so severe he couldn’t serve himself, headache and 6 kg weight loss associated with the treatment, the patient refused further therapy after one month and till September 2005 did not receive any treatment. The ALT level remained high during this period of time. At the time of his first visit, the physical examination revealed enlargement of the liver by 2.5 cm; however, his vital signs were normal. Investigations revealed the patient was positive for HCVAb, which were detected using the first-generation enzyme-linked immune-sorbent assay (ELISA); HBs Ag, HDVAb, HIVAb were negative. Quantitative plasma HCV RNA assay was detected by polymerase chain reaction (PCR) in real time (product of Interlab-Service, the Institute for Epidemiology, Moscow, Russia). (All investigations were carried out in the Reference laboratory of the Health Ministry, Tashkent, Uzbekistan). ALT level was 227 IU/L (5.4ULN-upper limit of norm), gamma-glutamiltransferase (GGT) level was 80 IU/L (1.6ULN). The results of thyroid function tests (serum T3, T4 and TTG) were normal. Results of serum Fe
机译：慢性丙型肝炎是全球范围内慢性肝病的主要原因，其自然发展史可能导致肝硬化并伴有肝衰竭，肝细胞癌和与肝有关的过早死亡。我们介绍了一个由慢性病毒C感染1基因型的24岁亚洲男子的案例，该病毒由利巴韦林治疗，该病毒被置于低水平激光辐射形成的区域并通过光导传输。所施予的治疗使病理过程稳定，同时血清丙氨酸-氨基转氨酶和γ-谷氨酰转移酶水平正常化，患者病情和生活质量得到改善。在应用上述方法时未观察到副作用。前言当前的慢性丙型肝炎（HCV）治疗方法是聚乙二醇干扰素α-2a或α-2b加利巴韦林，在关键性试验中联合治疗48周后，约有42％至52％的基因型患者具有持续的病毒学应答1感染1-3。慢性HCV治疗的主要目标是预防晚期肝相关的发病率和死亡率。但是，由于pegintereferon治疗的副作用，治疗中断率很高，因此传统上很难治疗HCV4。利巴韦林是一种口服核苷类似物，具有良好的耐受性，并且似乎以剂量依赖的方式降低HCV的感染性，但其作用方式尚不完全清楚5。利巴韦林的单药治疗与治疗结束时的生化反应和组织学改善有关，这会导致血清氨基转移酶水平正常化或接近正常化，但无法消除HCV RNA6,7。在本文中，我们介绍了一个由利巴韦林治疗的慢性HCV感染病例，该病例位于通过光导传输的低水平激光辐射形成的视野中，导致血清氨基转移酶水平长期持续正常化。据我们所知，这是用这种方法治疗慢性HCV感染患者的第一例病例报告。病例报告2005年9月，一名24岁的单身亚洲男子BMI-17.9出现在病毒学研究所的门诊部，主诉上腹部嗜睡，疲倦，周期性疼痛，恶心和烧心。他的病史包括他幼年时期的一次输血事件和2001年脚伤引起的外科手术。2005年1月，患者开始抱怨上述症状，检查发现丙氨酸转氨酶（ALT）水平高）。该患者的HCV RNA检测为阳性（定性）。 2005年3月，开始使用聚乙二醇化干扰素α（PEG-INF）和利巴韦林进行治疗。根据标准方案施用药物。但是，由于患者抱怨自己虚弱无力，无法忍受自己的头痛，头痛以及与治疗相关的体重减轻6公斤，因此该患者在一个月后拒绝接受进一步的治疗，直到2005年9月才接受任何治疗。在此期间，ALT水平仍然很高。在他第一次访问时，体格检查发现肝脏增大了2.5厘米。但是，他的生命体征正常。调查显示该患者的HCVAb呈阳性，已通过第一代酶联免疫吸附测定（ELISA）检测到。 HBs Ag，HDVAb，HIVAb阴性。通过聚合酶链反应（PCR）实时检测血浆HCV RNA定量（Interlab-Service产品，俄罗斯莫斯科流行病学研究所）。 （所有调查均在乌兹别克斯坦塔什干卫生部参考实验室进行）。 ALT水平为227 IU / L（5.4ULN，正常上限），γ-谷氨酰胺转移酶（GGT）水平为80 IU / L（1.6ULN）。甲状腺功能检查（血清T3，T4和TTG）正常。血清铁的结果

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号